List of Biotech, Pharmaceutical & Life Sciences companies in New Zealand - 11

We develop breakthrough diagnostic solutions for disorders of gastrointestinal function and motility.

Amaroq Therapeutics is a New Zealand-based biotechnology company focused on developing a new class of therapeutics that target lncRNA in cancer. Long non-coding RNAs are a relatively recently discovered class of molecules often referred to as “dark matter” of the human genome. These naturally occurring molecules do not code for proteins but fulfill important regulatory functions in the cell that could be exploited as a new therapeutic approach for multiple indications. Amaroq’s research team has discovered lncRNA molecules that are highly expressed in cancer cells, and once removed, cancer cell growth slows. Amaroq Therapeutics is developing innovative therapeutics to target lncRNAs for cancer treatment. Amaroq Therapeutics is funded by the Medical Research Commercialisation Fund, managed by life science venture capital firm Brandon Capital Partners, Otago Innovation Ltd, University of Otago, Cure Kids, and NZ Innovation Booster. The Company has been spun out of research from the University of Otago in Dunedin, New Zealand.

Healthy Animals. Let's Make It Happen, Together. At Argenta we've been dedicated to animal health from day one. Since 2006, we've been a trusted partner to clients who need our expertise, partnership and no-challenge-too-tough attitude to bringing innovative new animal health products to market. Because we are the only global CRO and CDMO specializing in animal health, we are uniquely able to offer clients of all sizes a comprehensive product development solution from Molecule to Market, at any scale. The day-to-day ethos that drives our company forward is a mission focused on global partnerships, a Molecule to Market approach, and of course, innovation. At the core of our business and our organisation is collaboration — among our global team and with our customers. Working together, we continually challenge ourselves and each other to continue to innovate to develop the best animal health technologies and products possible. From animal scientists to veterinarians to engineers and other industry experts, our 650+ strong global team is a passionate and diverse group united in their commitment to healthy animals. We operate from Research & Development locations and (EMA and FDA) GMP-approved Manufacturing sites in New Zealand, the US, the UK, Spain, and Germany. Our company was founded in New Zealand by Doug Cleverly, a scientist who naturally felt more at home in the lab solving problems than in the boardroom. Doug imbued the company with the spirit of Kiwi ingenuity and a global perspective. He saw a need in the market for an animal health company that could provide the highest quality services to customers of all sizes worldwide. To this day, we are still dedicated to animal health and our founder's legacy of problem-solving and inventiveness lives on within the organisation. Let's get in touch!

AVASA is a venture backed medical device company on a mission to simplify microsurgery by delivering the AVASA Coupler – an implantable device designed to help microsurgeons connect microvascular arteries and veins safer, simpler, and 80% faster than the current standard of care.

BioBrew Ltd develops and produces fresh and affordable microbial tools for human health and animal nutrition applications. BioBrew's products offer several key advantages over conventional probiotics: 1. Guaranteed Viability. Our products are the only probiotics that guarantee the number of microbes present throughout the entire shelf life period (as opposed to merely stating the number of microbes present at the time of manufacture). 2. We achieve this guaranteed viability in a product that does not require refrigeration prior to opening. 3. Our products combine high numbers of live & active probiotic lactobacilli with the beneficial organic acids produced by those microbes. Founded in 2009 with a product launch aimed at the New Zealand dairy sector, BioBrew Ltd has a vibrant and productive R&D program and has launched products for human health, companion animals, horses and environmental applications. The future of probiotics is fresh and fresh is BioBrew Ltd's specialty.

Curonz is a clinical stage biotechnology company with a patent portfolio and a focus on developing Neural Regeneration Peptides (NRPs) for various neurological conditions such as Lennox-Gastaut Syndrome (LGS) and Amyotrophic Lateral Sclerosis (ALS). The company aims to transform the Quality of Life of severely neurologically affected children and adults through its drug candidates.

DNAiTECH was founded in 2020 and is located in sunny Marlborough, Aotearoa-New Zealand. Marlborough is New Zealand's largest wine growing area. But DNAiTECH is adding a new flavour to Marlborough, we are the first biotechnology company founded in Marlborough, we are focusing on biomedical diagnostics, environmental testing and education. Our DNAiTECH technology enables real-time isothermal amplification of nucleic acid. The DNAiTECH is powerful because it integrates a small portable instrument with the imaging and data processing power of the Smartphone. The instrument is operated by the Smartphone via Bluetooth, with the phone camera providing the optical sensing of the DNA amplification and the data collection and processing via a specialized app. DNAiTECH can be used for any isothermal method for nucleic acid amplification. DNAiTECH is cost effective, has low power requirements and can be operated remotely with its internal lithium ion batteries.

In the past decade, the digitization of biological research has accelerated, and the science of biology has increasingly moved from the lab to the computer. Geneious aims to ease that process for scientists, allowing them to stay focused on science, while software handles the data management. Geneious creates powerful, integrated and visually appealing bioinformatics solutions, with a strong emphasis on ease of use and overall user experience. We are the market leaders in bioinformatics, constantly iterating and innovating to ensure our software solutions deliver everything our customers need. Headquartered in New Zealand with users in 125 countries worldwide, Geneious solutions enhance productivity in more than 4,000 universities, research institutes and businesses. In 2022, Geneious became part of Dotmatics, the world's largest and most powerful scientific R&D software platform. Combining an open data informatics framework with best in breed applications like Geneious Prime and Geneious Biologics, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Together, our company can better: connect science, data, and decision-making and ultimately drive meaningful transformation for our customers.

Kimer Med is a New Zealand biotech company, developing a pipeline of novel, broad-spectrum antiviral drug candidates. With success against 21 different viruses so far, we're taking on the global health challenge of viral disease and future pandemic threats. Our vision is to end the immense suffering caused by viral disease. There are currently around 220 viruses that cause disease in humans, and only 12 of them have an approved antiviral treatment available. In other words, 95% of viral diseases lack any approved treatment, resulting in enormous unmet medical needs worldwide. We have built and optimised a proprietary platform for the rapid development of broad-spectrum antiviral drug candidates to address these massive medical needs. Our goal is to bring to market a family of broad-spectrum antivirals to treat multiple diseases, and provide pandemic protection. To date we have achieved efficacy against 21 different viruses, and proved the broad-spectrum capabilities of our platform. We are currently in the lead-optimisation phase and nearing phase 1 clinical trials. In 2024, Kimer Med was recognised as one of the Fierce Biotech's 'Fierce 15 of 2024' - the best and brightest of biotech. We were also the recipients of a Merck Emerging Biotech Grant.

Rapid Medical Diagnostics is proud to be part of the commercialization and rollout of urine based Bilharzia (Schistosoma) diagnostic test strips. Production of the rapid test strips is the final result of years of research and extremely hard work by several people and institutions.

Ubiquitome's mission is to enable universal access to genomic information through ubiquitous cloud connected, genetic analysis devices.